Transarterial Chemoembolisation Plus Bevacizumab for Treatment of Hepatocellular Carcinoma
Status:
Terminated
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
Patients with liver cirrhosis and hepatocellular carcinoma will undergo transarterial
chemoembolisation (TACE) as clinically indicated and will be randomized to receive
bevacizumab or placebo every 2 weeks up to 1 year. Tumor response will be assessed using MR
of the liver and PET-scanning.
It will be tested whether the addition of bevacizumab as angiogenic inhibitor will slow down
tumor progression, reduce the need for re-embolisation and will improve patient survival.